Vasaprostan treatment of fibrosing alveolitis in patients withpulmonary hypertension

Cite item

Full Text


Aim. To study clinical efficacy of vasaprostan in patients with fibrosing alveolitis (FA) complicated by
pulmonary hypertension (PH), its effect on functional activity of platelets and endothelium, intensity of
free radical processes.
Material and methods. Seven FA patients were examined. They had either idiopathic FA or FA with
diffuse diseases of the connective tissues. The following methods were used to assess the effect: standard clinical tests, high resolution computer tomography, Doppler echocardiography, definition of the
complex thrombin-antithrombin (TAT) and thrombocytic factor 4 (TF-4). Generation ofoxugen active
forms by leukocytes was measured by luminol-dependent chemiluminescence. Morphological verification of the diagnosis was made by the results of open pulmonary biopsies.
Results. Vasaprostan reduced pressure in the pulmonary artery from 31,6 ± 2,31 to 19,58 ± 3,90 mm
Hg (р < 0,05) and coagulation parameters. TAT decreased after 2 and 8 weeks of treatment from
15,25 ± 4,5 to 5,1 ± 0,33 and 2,4 ± 0,31 pg/ml (p < 0,05). Initially low TF-4 (2,11 ± 0,39pg/ml)
elevated to the end of the treatment and reached values close to control (4,37 ± 0,25 pg/ml,
p < 0,05). Moreover, vasaprostan enhanced the ability of platelets to inhibit generation of active oxygen forms (from 0,9 ± 0,18 to 1,23 ± 0,16 r.u., p < 0,05) and thus depressed activity of lipid peroxidation.
Conclusion. Good effect of vasaprostan on platelet activity, free radical processes validates its use in
combined treatment of various FA forms for correction of PH, its complications and as an antifibrogenic agent.


  1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement: American Thoracic Society (ATS) and the European Respira- tory Society (ERS). Am. J. Respir. Crit. Care Med. 2000; 161 (2,pt 1): 646-664.
  2. Корнев Б. М., Попова Е. Н. Трудности диагностики интерстициальных болезней легких. Вестн. практ. врача 2003; 2: 12-17.
  3. Olschewski H., Ghofrani A., Wiedemann R. et al. Pulmonary hypertension. Internist (Berl.) 2002; 43 (12): 1501-1509.
  4. Fagan K. A. Pulmonary hypertension associated with connective tissue disease. Progr. Cardiovasc. Dis. 2002; 45 (3): 225- 234.
  5. Dorfmuller P., Humbert M., Capron F., Muller К. М. Pathology and aspects of pathogenesis in pulmonary arterial hypertension. Sarcoidos. Vase. Diffuse Lung 2003; 20 (1): 9-19.
  6. Беленков Ю. П., Чазова И. Е. Первичная легочная гипертония. Чазов Е. И. (ред.) Болезни сердца и сосудов. Руко водство для врачей. М.: Медицина; 1992; т. 3.
  7. Launey D., Hachulla E., Hatron P. Y. et al. Pulmonary hypertension screening in systemic scleroderma: a cohort study of 67 patients. Rev. Med. Interne 2001; 22 (9): 819-829.
  8. Yasui H., Gabazza E. C, Tagachi 0. et al. Decreased protein С activation is associated with abnormal collagen turnover in the intraalveolar space of patients with interstitial lung disease. Clin. Appl. Thromb. Hemost. 2000; 6 (4): 202-205.
  9. Rennard S. I., Beckmann J. D., Robbms R. A. Biology of airway epithelial cells. In: Crystal R. G., West J. B. (eds.) The lung: scientific foundation. New York: Raven Press; 1991. 157-167.
  10. Архипова Д. В., Корнев Б. М., Попова Е. Н. и др. Роль некоторых нейрогуморальных факторов в развитии легочной гипертензии при интерстициальных болезнях легких. Тер. арх. 2003; 3: 44-48.
  11. Макацария А. Д., Бицадзе О. В. Тромбофилии и противотромботическая терапия в акушерской практике. М.: Триада-Х; 2003.
  12. Bertina R. M. Molecular risk factor for thrombosis. Thromb. Haemost. 1999; 82 (2): 601-609.
  13. Been K. M., Beier J., Haas I. C. et al. Glutation deficiency of the lower respiratory tract in patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 2002; 19 (6): 1119-1123.
  14. Ishii Y., Hirano K., Morishima Y. et al. Early molecular and cellular events of oxidant-induced pulmonary fibrosis in rats. Toxicol. Appl. Pharmacol. 2000; 167 (3): 173-181.
  15. Mastruxzo C., Crimi N., Vancheri C. et al. Role of oxidative stress in pulmonary fibrosis. Monaldi Arch. Chest Dis. 2002; 57 (3-4): 173-176.
  16. Petkova D. К. Reduced expression of cyclooxygenase (COX) in idiopathic pulmonary fibrosis and sarcoidosis. Histopathology 2003; 43 (4): 381-386.
  17. Paramothayan N. S., Lasserson T. J., Wells A. U., Walters E. H. Prostacyclin for pulmonary hypertension (Cochrane Review). Cochrane Library 2003; Iss. 4.
  18. Мартынюк Т. В., Чазова И. Е., Масенко В. П. и др. Применение простагландина Е в комбинации с антагонистом кальция исрадипином у больных с первичной легочной гипертензией. Кардиология 1997; 8: 4-9.
  19. Решетняк Т. М., Алекберова 3. С, Насонова В. А. Применение вазапростана у больных системной красной волчанкой с антифосфолипидным синдромом. Тер. арх. 1999; 5: 40-47.
  20. Гусева Н. Г., Волков А. В., Мач Э. С. Применение вазапростана у больных системной склеродермией пожилого возраста. Клин, геронтол. 1999; 3: 73-74.
  21. Покровский А. В., Кошкин В. М., Коваленко В. И., Чупин А. В. Вазапростан в лечении критической ишемии нижних ко- Heidrich H. The importance of prostaglandin El in peripheral arterial occilisive disease. Am. J. Ther. 1997; 4: 351-352.
  22. Barst R. J., Rubin L. J., Long W. A. et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N.Engl. J. Med. 1996; 334: 296-301.
  23. McLaughlin V. V., Genthner D. E., Panella M. M. et al. Reduc tion in pulmonary vascular resistance with long-term epopros tenol (prostacyclin) therapy in primary pulmonary hyperten-sion. N. Engl. J. Med. 1998; 338: 273-277.
  24. Annie Pardo, Moises Selman. Idiopathic pulmonary fibrosis: new insights in its pathogenesis. Int. J. Biochem. Cell Biol. 2002; 34: 1534-1538.
  25. Bar-Shavit R., Benezra M., Sabbah V. et al. Thrombin as a multifunctional protein: induction of cell adhesion and proliferation. Am. J. Respir. Cell Mol. Biol. 1992; 6: 123-130.

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail:


© 2018-2021 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies